György M Buzás1, Hajnalka Györffy2, Ilona Széles3, Anna Szentmihályi4. 1. Department of Gastroenterology, Ferencváros Health Center, Budapest, Hungary. 2. 2nd Institute of Pathology, Semmelweis University, Budapest, Hungary. 3. Central Laboratory, 2nd District Health Center, Budapest, Hungary. 4. Department of Bacteriology, Johan Béla National Institute of Epidemiology, Budapest, Hungary.
Abstract
BACKGROUND: Following standard first-line triple therapies for Helicobacter pylori infection, up to 20% of patients require further eradication. OBJECTIVE: The aim of this study was to assess the effects of second-line triple therapies and third-line quadruple therapies for the eradication of H pylori. METHODS: This 7-week, prospective, crossover, controlled, second- and third-line trial was conducted at the Department of Gastroenterology, Ferencváros Health Center (Budapest, Hungary). Patients aged 18 to 80 years with duodenal ulcers and an H pylori infection resistant to first-line triple therapy (pantoprazole 40 mg BID + amoxicillin 1000 mg BID + clarithromycin 500 mg BID [PAC] given as tablets) received a different triple therapy regimen (ranitidine bismuth citrate 400 mg BID + metronidazole 500 mg BID + clarithromycin 500 mg BID [RBC-MC]) for 7 days (group 1A), and nonresponders after RBC + 2 antimicrobials received the pantoprazole-based regimen (group 1B). After secondary failure, patients were randomized to receive quadruple therapies: pantoprazole, amoxicillin, tetracycline, and either nitrofurantoin or bismuth subsalicylate (groups 2A and 2B). RESULTS:One hundred thirty-four patients were enrolled in the second-line study (56 men, 78 women; mean [SD] age, 51.1 [12.4] years; group 1A, 68 patients; group 1B, 66 patients). Subsequently, 41 (30.6%) of these patients were randomized to receive quadruple therapies. Using intent-to-treat (ITT) analysis, the eradication rates did not differ significantly (60.3% and 65.2% in groups 1A and 1B, respectively; 61.9% and 55.0% in groups 2A and 2B, respectively). Perprotocol eradication rates did not differ significantly (66.1% and 68.3% in groups 1A and 1B, respectively); however, the rates were significantly different in group 2A (66.7%) versus group 2B (55.5%) (P = 0.03).
RCT Entities:
BACKGROUND: Following standard first-line triple therapies for Helicobacter pylori infection, up to 20% of patients require further eradication. OBJECTIVE: The aim of this study was to assess the effects of second-line triple therapies and third-line quadruple therapies for the eradication of H pylori. METHODS: This 7-week, prospective, crossover, controlled, second- and third-line trial was conducted at the Department of Gastroenterology, Ferencváros Health Center (Budapest, Hungary). Patients aged 18 to 80 years with duodenal ulcers and an H pylori infection resistant to first-line triple therapy (pantoprazole 40 mg BID + amoxicillin 1000 mg BID + clarithromycin 500 mg BID [PAC] given as tablets) received a different triple therapy regimen (ranitidine bismuth citrate 400 mg BID + metronidazole 500 mg BID + clarithromycin 500 mg BID [RBC-MC]) for 7 days (group 1A), and nonresponders after RBC + 2 antimicrobials received the pantoprazole-based regimen (group 1B). After secondary failure, patients were randomized to receive quadruple therapies: pantoprazole, amoxicillin, tetracycline, and either nitrofurantoin or bismuth subsalicylate (groups 2A and 2B). RESULTS: One hundred thirty-four patients were enrolled in the second-line study (56 men, 78 women; mean [SD] age, 51.1 [12.4] years; group 1A, 68 patients; group 1B, 66 patients). Subsequently, 41 (30.6%) of these patients were randomized to receive quadruple therapies. Using intent-to-treat (ITT) analysis, the eradication rates did not differ significantly (60.3% and 65.2% in groups 1A and 1B, respectively; 61.9% and 55.0% in groups 2A and 2B, respectively). Perprotocol eradication rates did not differ significantly (66.1% and 68.3% in groups 1A and 1B, respectively); however, the rates were significantly different in group 2A (66.7%) versus group 2B (55.5%) (P = 0.03).
Authors: A Zullo; C Hassan; S M Campo; R Lorenzetti; I Febbraro; M De Matthaeis; D Porto; S Morini Journal: Aliment Pharmacol Ther Date: 2001-08 Impact factor: 8.171
Authors: A Leodolter; M Kulig; H Brasch; W Meyer-Sabellek; S N Willich; P Malfertheiner Journal: Aliment Pharmacol Ther Date: 2001-12 Impact factor: 8.171
Authors: S J Zanten; M Bradette; A Farley; D Leddin; T Lind; P Unge; E Bayerdörffer; R C Spiller; C O'Morain; P Sipponen; M Wrangstadh; L Zeijlon; P Sinclair Journal: Aliment Pharmacol Ther Date: 1999-03 Impact factor: 8.171
Authors: J P Gisbert; L González; X Calvet; N García; T López; M Roqué; R Gabriel; J M Pajares Journal: Aliment Pharmacol Ther Date: 2000-10 Impact factor: 8.171
Authors: J J Sung; F K Chan; J C Wu; W K Leung; R Suen; T K Ling; Y T Lee; A F Cheng; S C Chung Journal: Aliment Pharmacol Ther Date: 1999-08 Impact factor: 8.171
Authors: D Boixeda; F Bermejo; C Martín-De-Argila; A López-Sanromán; V Defarges; F Hernández-Ranz; J M Milicua; A García-Plaza Journal: Aliment Pharmacol Ther Date: 2002-08 Impact factor: 8.171